12-20-04

Attorney's Docket No.: 16863-002001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Li-Te Chin
Serial No. : 10/622,003
Filed : July 16, 2003
Title : PREPARATION OF FULLY HUMAN ANTIBODIES

Art Unit : 1644
Examiner : Unknown

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with the duty of disclosure as set forth in 37 C.F.R. §1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

**Foreign Patent**

1. WO 01/00678 A1, published January 4, 2001

**Articles**

2. Dercamp, C., et al. (2002). Depletion of human NK and CD8 cells prior to in vitro H1N1 flu vaccine stimulation increases the number of gamma interferon-secreting cells compared to the initial undepleted population in an ELISPOT assay. Clin Diagn Lab Immunol. 9(2):230-235.

3. Kobayashi, Y., et al. (2000). Cell-type specificity of l-leucyl l-leucine methyl ester. Biochem Biophys Res Commun. 272(3):687-690.

4. Ohlin, M., et al. (1992). Human MoAbs produced from normal, HIV-1-negative donors and specific for glycoprotein gp120 of the HIV-1 envelope. Clin Exp Immunol. 89(2):290-295.

5. Puhlmann, C.M., and Anderer, F.A. (1995). Optimizing production of human monoclonal IgG antibodies by *in vitro*-primed human PBMC: influence of $CD56^+$ NK cell depletion. Hybridoma. 14(4):391-396.

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EV584750910US

December 17, 2004
Date of Deposit

6. Trujillo, J.R., et al. (1998). Shared antigenic epitopes on the V3 loop of HIV-1 gp120 and proteins on activated human T cells. Virology. 246(1):53-62.

7. Zwick, M.B., et al. (2003). A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12. J Virol. 77(12):6965-6978.

These documents are being submitted before a first Office Action on the merits; therefore, no fee is required under 37 C.F.R. § 1.97(b). In the event an Office Action is mailed by the United States Patent and Trademark Office prior to receipt of this Supplemental Information Disclosure Statement, Applicants hereby make the statement specified in 37 C.F.R. §1.97(e) that each document contained herein was first cited in the European Search Report for the corresponding European application (EP 04 01 6838.7) within three (3) months of the filing date of this Supplemental Information Disclosure Statement. Therefore, no fee is required under 37 C.F.R. § 1.97(c). A copy of this European Search Report is also enclosed herewith.

By citing the above references, Applicants do not acquiesce or admit that any of these documents is "prior art" under 35 U.S.C. Applicants specifically reserve the right, where appropriate, to antedate any of the cited documents by an appropriate showing under 37 C.F.R. §1.131, §1.604, §1.608 or any other suitable means.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: December 17, 2004

Ping F. Hwung
Reg. No. 44,164

Fish & Richardson P.C.
500 Arguello Street, Suite 500
Redwood City, California 94063
Telephone: (650) 839-5070
Facsimile: (650) 839-5071

50251945.doc

| Substitute Form PTO-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 16863-002001 | Application No. 10/622,003 |
|---|---|---|---|
| **Supplemental Information Disclosure Statement by Applicant** (Use several sheets if necessary) (37 CFR §1.98(b)) | | Applicant: Li-Te Chin | |
| | | Filing Date: July 16, 2003 | Group Art Unit: 1644 |

**U.S. Patent Documents**

| Examiner Initial | Desig. ID | Document Number | Publication Date | Patentee | Class | Subclass | Filing Date If Appropriate |
|---|---|---|---|---|---|---|---|
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |

**Foreign Patent Documents or Published Foreign Patent Applications**

| Examiner Initial | Desig. ID | Document Number | Publication Date | Country or Patent Office | Class | Subclass | Translation Yes | Translation No |
|---|---|---|---|---|---|---|---|---|
| | AD | WO 01/00678 A1 | 01/04/2001 | EPO | | | | |
| | AE | | | | | | | |
| | AF | | | | | | | |

**Other Documents (include Author, Title, Date, and Place of Publication)**

| Examiner Initial | Desig. ID | Document |
|---|---|---|
| | AG | Dercamp, C., et al. (2002). Depletion of human NK and CD8 cells prior to in vitro H1N1 flu vaccine stimulation increases the number of gamma interferon-secreting cells compared to the initial undepleted population in an ELISPOT assay. Clin Diagn Lab Immunol. 9(2):230-235. |
| | AH | Kobayashi, Y., et al. (2000). Cell-type specificity of l-leucyl l-leucine methyl ester. Biochem Biophys Res Commun. 272(3):687-690. |
| | AI | Ohlin, M., et al. (1992). Human MoAbs produced from normal, HIV-1-negative donors and specific for glycoprotein gp120 of the HIV-1 envelope. Clin Exp Immunol. 89(2):290-295. |
| | AJ | Puhlmann, C.M., and Anderer, F.A. (1995). Optimizing production of human monoclonal IgG antibodies by in vitro-primed human PBMC: influence of CD56+ NK cell depletion. Hybridoma. 14(4):391-396. |
| | AK | Trujillo, J.R., et al. (1998). Shared antigenic epitopes on the V3 loop of HIV-1 gp120 and proteins on activated human T cells. Virology. 246(1):53-62. |
| | AL | Zwick, M.B., et al. (2003). A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12. J Virol. 77(12):6965-6978. |

| Examiner Signature | Date Considered |
|---|---|
| EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |